These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 33070218)
21. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis. Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582 [TBL] [Abstract][Full Text] [Related]
22. Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction. Vicent L; Cinca J; Vazquez-García R; Gonzalez-Juanatey JR; Rivera M; Segovia J; Pascual-Figal D; Bover R; Worner F; Delgado-Jiménez J; Fernández-Avilés F; Martínez-Sellés M Intern Med J; 2019 Dec; 49(12):1505-1513. PubMed ID: 30887642 [TBL] [Abstract][Full Text] [Related]
23. Beneficial and harmful effects of sacubitril/valsartan in patients with heart failure: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. Nielsen EE; Feinberg JB; Bu FL; Hecht Olsen M; Raymond I; Steensgaard-Hansen F; Jakobsen JC Open Heart; 2020 Nov; 7(2):. PubMed ID: 33257469 [TBL] [Abstract][Full Text] [Related]
25. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Santema BT; Ouwerkerk W; Tromp J; Sama IE; Ravera A; Regitz-Zagrosek V; Hillege H; Samani NJ; Zannad F; Dickstein K; Lang CC; Cleland JG; Ter Maaten JM; Metra M; Anker SD; van der Harst P; Ng LL; van der Meer P; van Veldhuisen DJ; Meyer S; Lam CSP; ; Voors AA Lancet; 2019 Oct; 394(10205):1254-1263. PubMed ID: 31447116 [TBL] [Abstract][Full Text] [Related]
26. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW; Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013 [TBL] [Abstract][Full Text] [Related]
27. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. Maggioni AP; Anand I; Gottlieb SO; Latini R; Tognoni G; Cohn JN; J Am Coll Cardiol; 2002 Oct; 40(8):1414-21. PubMed ID: 12392830 [TBL] [Abstract][Full Text] [Related]
28. Tissue angiotensin-converting enzyme inhibitors for the prevention of cardiovascular disease in patients with diabetes mellitus without left ventricular systolic dysfunction or clinical evidence of heart failure: a pooled meta-analysis of randomized placebo-controlled clinical trials. Saha SA; Molnar J; Arora RR Diabetes Obes Metab; 2008 Jan; 10(1):41-52. PubMed ID: 18095949 [TBL] [Abstract][Full Text] [Related]
29. Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. Lam PH; Dooley DJ; Fonarow GC; Butler J; Bhatt DL; Filippatos GS; Deedwania P; Forman DE; White M; Fletcher RD; Arundel C; Blackman MR; Adamopoulos C; Kanonidis IE; Aban IB; Patel K; Aronow WS; Allman RM; Anker SD; Pitt B; Ahmed A Eur J Heart Fail; 2018 Feb; 20(2):359-369. PubMed ID: 28980368 [TBL] [Abstract][Full Text] [Related]
30. Heart failure with preserved ejection fraction has a better long-term prognosis than heart failure with reduced ejection fraction in old patients in a 5-year follow-up retrospective study. Kontogeorgos S; Thunström E; Johansson MC; Fu M Int J Cardiol; 2017 Apr; 232():86-92. PubMed ID: 28100428 [TBL] [Abstract][Full Text] [Related]
31. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine? Ahmed A J Am Geriatr Soc; 2002 Jul; 50(7):1297-300. PubMed ID: 12133029 [TBL] [Abstract][Full Text] [Related]
32. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction. Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035 [TBL] [Abstract][Full Text] [Related]
33. Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies. Fukuta H; Goto T; Wakami K; Ohte N Heart Fail Rev; 2017 Nov; 22(6):775-782. PubMed ID: 28702858 [TBL] [Abstract][Full Text] [Related]
34. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers for ischemic heart disease. Baker WL; Coleman CI; Kluger J; Reinhart KM; Talati R; Quercia R; Phung OJ; White CM Ann Intern Med; 2009 Dec; 151(12):861-71. PubMed ID: 20008762 [TBL] [Abstract][Full Text] [Related]
35. The treatment gap in patients with chronic systolic heart failure: a systematic review of evidence-based prescribing in practice. Chin KL; Skiba M; Tonkin A; Reid CM; Liew D; Krum H; Hopper I Heart Fail Rev; 2016 Nov; 21(6):675-697. PubMed ID: 27465132 [TBL] [Abstract][Full Text] [Related]
36. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry. Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066 [TBL] [Abstract][Full Text] [Related]
37. A Systematic Review of Outcomes Associated With Withholding or Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Before Noncardiac Surgery. Hollmann C; Fernandes NL; Biccard BM Anesth Analg; 2018 Sep; 127(3):678-687. PubMed ID: 29381513 [TBL] [Abstract][Full Text] [Related]
38. Discharge use of angiotensin receptor blockers provides comparable effects with angiotensin-converting enzyme inhibitors on outcomes in patients hospitalized for heart failure. Tsuchihashi-Makaya M; Furumoto T; Kinugawa S; Hamaguchi S; Goto K; Goto D; Yamada S; Yokoshiki H; Takeshita A; Tsutsui H; Hypertens Res; 2010 Mar; 33(3):197-202. PubMed ID: 19960016 [TBL] [Abstract][Full Text] [Related]
39. Effects of angiotensin receptor blocker at discharge in patients with heart failure with reduced ejection fraction: Korean Acute Heart Failure (KorAHF) registry. Choi KH; Lee GY; Choi JO; Jeon ES; Lee HY; Cho HJ; Lee SE; Kim MS; Kim JJ; Hwang KK; Chae SC; Baek SH; Kang SM; Choi DJ; Yoo BS; Kim KH; Park HY; Cho MC; Oh BH Int J Cardiol; 2018 Apr; 257():168-176. PubMed ID: 29506690 [TBL] [Abstract][Full Text] [Related]
40. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Dagenais GR; Pogue J; Fox K; Simoons ML; Yusuf S Lancet; 2006 Aug; 368(9535):581-8. PubMed ID: 16905022 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]